Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Taxes (2016 - 2018)

Enanta Pharmaceuticals (ENTA) has disclosed Current Taxes for 5 consecutive years, with $5.9 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Current Taxes fell 42.89% year-over-year to $5.9 million, compared with a TTM value of $5.9 million through Dec 2018, down 42.89%, and an annual FY2018 reading of $1.4 million, down 85.07% over the prior year.
  • Current Taxes was $5.9 million for Q4 2018 at Enanta Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Across five years, Current Taxes topped out at $16.9 million in Q4 2014 and bottomed at $1.2 million in Q3 2015.
  • Average Current Taxes over 5 years is $6.8 million, with a median of $5.6 million recorded in 2018.
  • The sharpest move saw Current Taxes skyrocketed 31.99% in 2016, then plummeted 85.07% in 2018.
  • Year by year, Current Taxes stood at $16.9 million in 2014, then tumbled by 70.76% to $4.9 million in 2015, then plummeted by 40.45% to $2.9 million in 2016, then surged by 248.64% to $10.3 million in 2017, then plummeted by 42.89% to $5.9 million in 2018.
  • Business Quant data shows Current Taxes for ENTA at $5.9 million in Q4 2018, $1.4 million in Q3 2018, and $5.4 million in Q1 2018.